UK Myocardial Infarction Market, Size, Share, Analysis Report & Forecast to 2026

UK myocardial infarction (MI) market is estimated to grow considerably at a CAGR of around 7.2% during the forecast period. UK has one of the finest healthcare systems in the EU region which enables it to provide quality healthcare to the individual citizens. UK has the highest number of CVD, CHD, MI, stroke, heart failure, atrial fibrillation, and other heart patients. According to the British Heart Foundation, more than one- a fourth of the fatalities in UK are due to CVD, which is responsible for around 1.6 million fatalities each year. The critical factors that are leading to CVD, CHD, MI, stroke, and other heart diseases include work-related stress, depression, excessive consumption of alcohol, excessive smoking, hypertension, diabetes, obesity, and poor diet which includes cholesterol.

Free Sample Copy @ https://www.omrglobal.com/request-sample/uk-myocardial-infarction-market

The market study of the UK myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

A Full Report of UK Myocardial Infarction Market is Available at:
https://www.omrglobal.com/industry-reports/uk-myocardial-infarction-market

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

The companies which are contributing to the growth of the UK myocardial infarction market include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Novartis AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Medtronic PLC, and Merck KGaA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in October 2019, AstraZeneca PLC’s Farxiga was approved in the US. The drug aids in reducing the risk of hospitalization for heart failure in patients with type-2 diabetes. Thus, through this approval, the company seeks to extend its product portfolio and serve a large customer base across the globe.

UK Myocardial Infarction Market – Segmentation
by Type
Non-ST-elevation myocardial infarction (NSTEMI)
ST-elevation myocardial infarction (STEMI)
Silent Heart Attacks
by Device
Left Ventricular Assist Device (LVAD)
Pacemaker
Catheters
Implantable Cardioverter-Defibrillator (ICD)
Others (Stent Graft)
by Diagnosis
Electrocardiography (ECG)
Chest X-Ray
Computed Tomography (CT Scan)
Echocardiography
Others (Blood Test)
by Treatment
Medication
Analgesics
Thrombolytic
Antiplatelet Agents
Glycoprotein IIb/IIIa Inhibitors
Others (Beta-Adrenergic Blockers)
Surgery
Angioplasty
Bypass Surgery
Heart Transplant
by End-User
Hospital & Clinics
Ambulatory Surgical Centers
Research Institutes

Company Profiles
Abbott Laboratories Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
Boston Scientific Corp.
Bristol-Myers Squibb Co.
Eli Lilly and Co.
GlaxoSmithKline Plc
Johnson & Johnson Services, Inc.
Koninklijke Philips N.V.
Medtronic PLC
Merck KGaA
Novartis AG
Pfizer Inc.
Portola Pharmaceutical Inc.
Sanofi SA
Siemens AG

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-myocardial-infarction-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

Leave a comment

Your email address will not be published. Required fields are marked *